Complications, morbidity and mortality of nonalcoholic fatty liver disease.

This narrative review provides an overview of the current literature on main complications, morbidity and mortality of this common and burdensome liver disease.

Prognostic value of NAFLD in the elderly

V. Tallarico et al. (Division of Internal Medicine, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy) investigated the independent prognostic value of NAFLD on overall mortality in the elderly.

The International Liver congress (ILC) 2020

Given the ongoing developments with COVID-19, ILC 2020 is postponed to 25-28 August 2020 in London at the same venue.

At the International Liver Congress 2020, EASL is turning its attention to health in daily life and its importance in protecting the liver. Doctors, patients and patient groups, allied health professionals and policymakers will discuss the important new insights and information to help combat liver disease.

Pre-clinical study with Lanifibranor - Prof Gracia-Sancho

Prof Gracia-Sancho, Spain, discusses his oral presentation at the Liver meeting 2019 in Boston and the reasons why PPAR agonists could be a very valuable therapeutic option for the treatment of advanced chronic liver disease.

Flaxseed oil in the context of a weight loss program ameliorates fatty liver grade in patients with non-alcoholic fatty liver disease: a randomized double-blind controlled trial

In this study, Masoumeh Akhlaghi et al. investigated the effect of flaxseed oil, as a rich source of alpha-linolenic acid, on fatty liver and cardiometabolic risk factors in patients with non-alcoholic fatty liver disease.

Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease

This study by Henson JB et al. aimed to determine the factors associated with incident cardiovascular events in a prospective cohort of individuals with biopsy-proven NAFLD without pre-existing cardiovascular disease.

The role of PPARs in NASH fibrogenesis

Prof Michael Roden, Germany discusses the reasons why patients with NASH have an increased cardiovascular risk and the potential for PPAR agonists to improve outcomes. This video was filmed in Boston during the Liver meeting 2019.

What can we expect from PPAR agonists in the treatment of NASH?

Prof Manal Abdelmalek, USA highlights the role that PPAR agonists could play in the treatment of NASH. This video was filmed in Boston during the Liver meeting 2019.

The role of PPARs in NASH fibrogenesis

Prof Gyongyi Szabo, USA discusses the role of PPARs in NASH fibrogenesis. This video was filmed in Boston during the Liver meeting 2019.

The role of PPARs in inflammation

Prof Frank Tacke, Germany, discusses the role of PPARs in adipose tissue and liver inflammation. This video was filmed in Boston during the Liver meeting 2019.